Answers are grounded in this paper and cite their sources.
Introduction: New-generation hormonal therapies such as abiraterone acetate (AA) in combination with prednisone or prednisolone (AAP) have improved the overall survival (OS) in patients with chemotherapy-pretreated and naïve metastatic castration-resistant prostate cancer (mCRPC). More recently, AAP has demonstrated efficacy in newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and has received expanded approval for this indication.Areas covered: This review is intended to provide a thorough overview of AA as the first-in-class and only currently approved steroid 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor for prostate cancer. To the best of our knowledge, this is the most comprehensive review of AAP that covers all three indications: mCRPC in the pre- and post-chemotherapy setting, and mHSPC. We describe, among other things, the mechanism of action of AA and review data on its efficacy and safety from phase 1, 2 and the pivotal phase 3 clinical trials that support its use in the mentioned approved indications.Expert opinion: AAP has been established over the past 10 years and was added to the WHO list of essential medicines in 2019 through an evidence-based selection process in which quality, safety, efficacy, and cost-effectiveness are key criteria, highlighting its role in the current therapeutic landscape of prostate cancer management.
No takes yet. Share an insight, caveat, or question.
Gschwend et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: